<DOC>
	<DOCNO>NCT00865124</DOCNO>
	<brief_summary>Aldosterone significant mediator cardiovascular injury associate heart failure cardiovascular benefit mineralocorticoid receptor blockade additive angiotensin convert enzyme inhibitor angiotensin II receptor blocker . This study test hypothesis MR antagonists exert beneficial cardiovascular effect , specifically decrease vascular injury improve vascular function.A randomize , double-blind study conduct , subject Type 2 Diabetes Mellitus undergo series assessment test heart , blood vessel , kidney function baseline , 2 6 month treatment one follow drug : 1. spironolactone 2. hydrochlorothiazide plus potassium 3. placebo . In event insufficient fund , randomization placebo arm stop primary assessment outcome occur baseline 6 month treatment .</brief_summary>
	<brief_title>Role Mineralocorticoid Receptor Diabetic Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>age 1870 year type 2 diabetes mellitus without hypertension ischemic change rest electrocardiogram , clinical evidence heart disease ( angina , heart failure , unstable angina ) , cerebrovascular peripheral vascular disease , significant cardiac arrhythmia , aortic stenosis , 2nd 3rd degree atrioventricular block , sinus node disease , symptomatic bradycardia , bronchospastic lung disease active wheezing , know hypersensitivity adenosine , hemoglobin A1C &gt; 8.5 % , * gout ( If already take HCTZ ) , use Rosiglitazone , ** eGFR &lt; 60 ml/min , serum potassium &gt; 5.0 mmol/L , use potassiumsparing diuretic , ** current smoker , * pregnancy , renal disease relate diabetes mellitus , uncontrolled hypertension , systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg , * use cyclic hormone replacement therapy past intolerance ACE inhibitor therapy major medical illness . Subjects evidence previous myocardial infarction first adenosinestimulated PET study withdrawn study . Screening systolic blood pressure &lt; 105 mm Hg antihypertensive medication Subjects enroll study proceed inpatient evaluation runin period adjustment medication , diet habit lead improve glucose control ( equivalent HbA1c &lt; 8.5 % ) , control hypertension cessation smoking . Subjects currently take medication qualify screen visit . If medication recently stop subject 's physician , may screen baseline assessment protocol must occur 3 month stop .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>